JNK

c-Jun N-terminal kinase

JNK

JNK Isoform Specific Products:

JNK Isoform Comparison

JNK Related Products (250)
Antibodies (16)
JNK Isoform Comparison

By Effects:	Controls (3) Inhibitors (172) Agonists (2) Degrader (1) Activators (48) Modulator (1) Inducers (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-13326

ASP3026		99.88%
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research.

HY-100538A

DTP3 TFA	Inhibitor	98.00%
DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway.

HY-101287

MPT0B392	Activator	99.63%
MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line.

HY-112402

SP 600125, negative control	Control	98.05%
SP 600125，negative control (SPM1) is an alkyl derivative of pyrazoloanthrone，which can be used as a negative control for SP600125 (HY-12041).

HY-14928

Lobeglitazone	Inhibitor
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone is the orally active agonist for PPAR with EC₅₀ of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties.

HY-146195

MAPK-IN-1	Inhibitor
MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC₅₀ of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research.

HY-107600

IQ-3	Inhibitor	99.38%
IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively.

HY-10412

CEP-1347	Inhibitor	98.50%
CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects. CEP-1347 blocks JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase). As an inhibitor of MDM4, CEP-1347 can more effectively inhibit the growth of glioma cells expressing wild-type p53.

HY-N7110

6-Hydroxyflavone	Activator	99.95%
6-Hydroxyflavone is an orally effective flavonoid compound. 6-Hydroxyflavone can inhibit LPS (HY-D1056) -induced NO production and has anti-inflammatory effects. 6-Hydroxyflavone promotes osteoblast differentiation by activating AKT, ERK 1/2 and JNK signaling pathways. 6-Hydroxyflavone has an inhibitory effect on bovine hemoglobin (BHb) glycosylation. 6-Hydroxyflavone has a kidney protective effect. In addition, 6-Hydroxyflavone enhances GABA-induced current through the Benzodiazepine sites of γ-aminobutyric acid (GABA_A) receptors. 6-Hydroxyflavone shows a clear preference for α2 - and α3 - subtypes, which play an anti-anxiety role.

HY-151929

JNK3 inhibitor-4	Inhibitor	99.37%
JNK3 inhibitor-4 is a potent inhibitor of JNK3 (IC₅₀=1.0 nM) based on 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile. JNK3 inhibitor-4 shows excellent selectivity over other protein kinases including isoforms JNK1 (IC₅₀=143.9 nM) and JNK2 (IC₅₀=298.2 nM). JNK3 inhibitor-4 has neuroprotective effect and predicated blood-brain barrier permeability.

HY-100233

IQ-1S free acid	Inhibitor	99.28%
IQ-1S free acid is a prospective inhibitor of NF-κB/activating protein 1 (AP-1) activity with an IC₅₀ of 2.3±0.41 μM. IQ-1S free acid has binding affinity (K_d values) in the nanomolar range for all three JNKs with K_ds of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2, respectively.

HY-152142

DN-1289	Inhibitor	99.63%
DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase (DLK; IC₅₀=17 nM) and leucine zipper-bearing kinase (LZK; IC₅₀=40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability.

HY-P0069A

L-JNKI-1	Inhibitor	99.01%
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.

HY-P2246

JTP10-△-TATi TFA	Inhibitor	98.49%
JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

HY-108419

WHI-P258		99.43%
WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated K_i of 72 µM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM.

HY-N6872

Actein	Activator	99.25%
Actein, a triterpene glycoside, shows an inhibitory effect on cancer cells, which is isolated from the rhizomes of Cimicifuga foetida. Actein suppresses cell proliferation, induces autophagy and apoptosis through promoting ROS/JNK activation, and blunting AKT pathway in bladder cancer. Actein has little toxicity in vivo.

HY-108016

Peruvoside	Inhibitor	99.32%
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib.

HY-14928A

Lobeglitazone sulfate	Inhibitor	99.63%
Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate is the orally active agonist for PPAR with EC₅₀ of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone sulfate is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties.

HY-N4126

6-Demethoxytangeretin	Inhibitor	99.37%
6-Demethoxytangeretin is a flavonoid compound that can be isolated from Citrus reticulata. 6-Demethoxytangeretin has anti-inflammatory and anti-allergic activities and can inhibit the production of IL-6 and the expression of related genes in human mast cells through the ALK and MAPK pathways. 6-Demethoxytangeretin can promote CRE-mediated transcription in hippocampal neurons.

HY-P2319A

OVA-E1 peptide TFA	Activator	98.03%
OVA-E1 peptide TFA, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

SP600125	JNK1, IC₅₀: 40 nM	JNK2, IC₅₀: 40 nM	JNK3, IC₅₀: 90 nM		99.73%
Anisomycin				JNK	99.82%
JNK-IN-8	JNK1, IC₅₀: 4.7 nM	JNK2, IC₅₀: 18.7 nM	JNK3, IC₅₀: 1 nM		99.67%
Chloramphenicol				JNK	99.93%
Astragaloside IV				JNK	99.93%
Guggulsterone				JNK	99.83%
Tomatidine				JNK	≥98.0%
Isovitexin	JNK1	JNK2			99.82%
JNK Inhibitor VIII	JNK1, Ki: 2 nM JNK1, IC₅₀: 45 nM	JNK2, Ki: 4 nM JNK2, IC₅₀: 160 nM	JNK3, Ki: 52 nM		99.46%
Tanzisertib	JNK1, IC₅₀: 61 nM	JNK2, IC₅₀: 7 nM	JNK3, IC₅₀: 6 nM		99.87%
Ginsenoside Re				JNK	99.22%
CC-90001	JNK1	JNK2			99.75%
JNK-IN-7	JNK1, IC₅₀: 1.5 nM	JNK2, IC₅₀: 2 nM	JNK3, IC₅₀: 0.7 nM		98.92%
Bentamapimod	JNK1, IC₅₀: 80 nM	JNK2, IC₅₀: 90 nM	JNK3, IC₅₀: 230 nM		99.32%
AS601245	hJNK1, IC₅₀: 150 nM	hJNK2, IC₅₀: 220 nM	hJNK3, IC₅₀: 70 nM		98.83%
DB07268	JNK1, IC₅₀: 9 nM				99.92%
D-JNKI-1				JNK	99.29%
CC-401 hydrochloride				JNK, Ki: 25-50 nM	99.35%
BI-78D3				JNK, IC₅₀: 280 nM	99.85%
SR-3306				JNK	99.0%
TNG348	JNK1				99.74%
Seratrodast				JNK	98.86%
Juglanin				JNK	99.90%
J30-8			JNK3, IC₅₀: 40 nM		99.90%
Tomatidine hydrochloride				JNK	99.58%
Indirubin-3′-oxime	JNK1, IC₅₀: 0.8 μM	JNK2, IC₅₀: 1.4 μM	JNK3, IC₅₀: 1 μM		99.10%
TCS JNK 5a		JNK2, pIC₅₀: 6.5	JNK3, pIC₅₀: 6.7		99.40%
Loureirin B				JNK	99.16%
MPT0B392				JNK	99.63%
IQ-3	JNK1, Kd: 0.24 μM	JNK2, Kd: 0.29 μM	JNK3, Kd: 0.066 μM		99.38%
CEP-1347	JNK1				98.50%
JNK3 inhibitor-4	JNK1, IC₅₀: 143.9 nM	JNK2, IC₅₀: 298.2 nM	JNK3, IC₅₀: 1.0 nM		99.37%
IQ-1S free acid	JNK1, Kd: 240 nM	JNK2, Kd: 360 nM	JNK3, Kd: 100 nM		99.28%
L-JNKI-1				JNK	99.01%
JTP10-△-TATi TFA	JNK1, IC₅₀: 1.16 μM	JNK2, IC₅₀: 92 nM	JNK3, IC₅₀: 1.2 μM		98.49%
SR-3576			JNK3, IC₅₀: 7 nM		98.2%
SX 011	JNK1, IC₅₀: > 300 (Pan)	JNK2, IC₅₀: 100 nM			99.33%
JNK-IN-13		JNK2, IC₅₀: 500 nM	JNK3, IC₅₀: 290 nM
Salicortin				JNK
JTP10-△-R9 TFA	JNK1, IC₅₀: 1.1 μM	JNK2, IC₅₀: 89 nM	JNK3, IC₅₀: 1.2 μM		99.80%
CC-401				JNK, Ki: 25-50 nM	98.60%
(-)-Zuonin A	JNK1, IC₅₀: 1.7 μM	JNK2, IC₅₀: 2.9 μM	JNK3, IC₅₀: 1.74 μM		99.99%
Sugiol	JNK1	JNK2			99.88%
IQ-1S	JNK1, Kd: 390 nM	JNK2, Kd: 360 nM	JNK3, Kd: 87 nM
JNK-1-IN-1	JNK1
JNK-IN-11	JNK1, IC₅₀: 1.8 μM	JNK2, IC₅₀: 21.4 μM	JNK3, IC₅₀: 2.2 μM		98.01%
Aloisine A				JNK, IC₅₀: 3-10 μM
JAK3-IN-13	JNK1, IC₅₀: 4728 nM	JNK2, IC₅₀: 2039 nM	JNK3, IC₅₀: 8 nM
GSK3-IN-10			JNK3, IC₅₀: 2900 nM
Ginsenoside Re (Standard)				JNK
JNK3 inhibitor-7	JNK1, IC₅₀: 1039 nM	JNK2, IC₅₀: 973 nM	JNK3, IC₅₀: 53 nM
Lucidone				JNK
PT109	JNK1, IC₅₀: 0.143 μM	JNK2, IC₅₀: 0.831 μM	JNK3, IC₅₀: 0.285 μM
ERK2 IN-5			JNK3, Ki: 550 nM
Cernuumolide J			JNK3
YL5084	JNK1, IC₅₀: 2173 nM	JNK2, IC₅₀: 70 nM	JNK3, IC₅₀: 84 nM
JNK3 inhibitor-5	JNK1, IC₅₀: 82.7 nM	JNK2, IC₅₀: 29.4 nM	JNK3, IC₅₀: 0.379 nM
JNK3 inhibitor-8	JNK1, IC₅₀: >10000 nM	JNK2, IC₅₀: 2203 nM	JNK3, IC₅₀: 21 nM
PROTAC JNK1-targeted-1	JNK1, DC₅₀: 10 nM
MR2938				JNK
JNK3 inhibitor-3	JNK1, IC₅₀: 147.8 nM	JNK2, IC₅₀: 44 nM	JNK3, IC₅₀: 4.1 nM
JNK-IN-14	JNK1, IC₅₀: 1.82 nM	JNK2, IC₅₀: 10.5 nM	JNK3, IC₅₀: 10.5 nM
JNK-1-IN-4	JNK1, IC₅₀: 2.7 nM	JNK2, IC₅₀: 19.0 nM	JNK3, IC₅₀: 9.0 nM
TOPK-p38/JNK-IN-1				JNK
ZG-10	JNK1, IC₅₀: 809 nM	JNK2, IC₅₀: 1140 nM	JNK3, IC₅₀: 709 nM
JNK3 inhibitor-9			JNK3, IC₅₀: 12 nM
JNK-1-IN-5	JNK1
Ophiopogonin B				JNK
Cyy-272	JNK1, IC₅₀: 1.25 μM	JNK2, IC₅₀: 1.07 μM	JNK3, IC₅₀: 1.24 μM
JNK3 inhibitor-2	JNK1, IC₅₀: >100 μM	JNK2, IC₅₀: >100 μM	JNK3, IC₅₀: 0.25 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.

JNK

JNK

JNK Isoform Specific Products:

JNK Isoform Specific Products:

JNK Related Products (250)

Antibodies (16)

JNK Isoform Comparison

JNK Related Products (250):